DFB Pharmaceuticals
Practical innovations for life

Drug Development

Development Programs

 

Oncology

NanoPac® Nanoparticle Paclitaxel

NanoPac® Nanoparticle Paclitaxel sterile suspension for intraperitoneal (IP) infusion targeting

  • Ovarian cancer

NanoPac® Nanoparticle Paclitaxel sterile suspension for direct injection targeting

  • Prostate cancer
  • Pancreatic cancer
  • Pancreatic cysts

NanoPac® Nanoparticle Paclitaxel suspension in a proprietary topical base targeting

  • Skin metastases secondary to metastatic breast cancer

NanoPac® Nanoparticle Paclitaxel powder for nebulized lung inhalation targeting

  • Non-small cell lung cancer (NSCLC)

NanoDoce® Nanoparticle Docetaxel

NanoDoce® Nanoparticle Docetaxel sterile suspension for direct local injection targeting

  • Muscle invasive bladder cancer

NanoDoce® Docetaxel sterile suspension for intravesicle instillation targeting

  • Non-muscle invasive bladder cancer

Dermatology

NanoPac® Nanoparticle Paclitaxel suspension in a proprietary topical base targeting

  • Actinic keratosis
  • Psoriasis

Women's Health

NanoPac® Nanoparticle Paclitaxel suspension in a proprietary topical base targeting

  • Skin metastases secondary to metastatic breast cancer
  • Cervical intraepithelial neoplasia (CIN)
  • Vulvar intraepithelial neoplasia (VIN)

NanoPac® Nanoparticle Paclitaxel sterile suspension for intraperitoneal (IP) infusion targeting

  • Endometriosis
  • Surgical adhesions

Development Timelines

Development timeline by date (click to expand)